熊婧,陈维

• 1:同济大学附属第十人民医院心内科

摘要(Abstract)：

<正>心房颤动(房颤)是一种极为常见的心律失常。全世界范围内约3200万房颤患者,美国约500万房颤患者~([1])。35～59岁的中国人群中房颤患病率为0.42%,大于60岁的中国人群中房颤患病率为1.83%~([2])。房颤是造成卒中、充血性心力衰竭、全因死亡的重要危险因素。左心耳是卒中最主要的来源~([3])。左心耳形状、肌小梁走行、梳状肌形状、房颤相关的炎症水平、心房重构以及血液高凝状态,都与血栓形成

关键词(KeyWords)： 左心耳封堵术;心房颤动;卒中

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 熊婧,陈维

参考文献(References)：

• [1]Mozaffarian D,Benjamin EJ,Benjamin EJ,et al.Heart disease and stroke statistics-2016 update:a report from the American Heart Association.Circulation,2016,133(4):e38-e360.
• [2]Li Y,Wu YF,Chen KP,et al.Prevalence of atrial fibrillation in China and its risk factors.Biomed Environ Sci,2013,26(9):709-716.
• [3]Blackshear JL,Odell JA.Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation.Ann Thorac Surg,1996,61(2):755-759.
• [4]Maybrook R,Pillarisetti J,Yarlagadda V,et al.Electrolyte and hemodynamic changes following percutaneous left atrial appendage ligation with the LARIAT device.J Interv Card Electrophysiol,2015,43(3):245-251.
• [5]Di Biase L,Burkhardt JD,Mohanty P,et al.Left atrial appendage:an underrecognized trigger site of atrial fibrillation.Circulation,2010,122(2):109-118.
• [6]Yamada T,Mc Elderry HT,Allison JS,et al.Focal atrial tachycardia originating from the epicardial left atrial appendage.Heart Rhythm,2008,5(5):766-777.
• [7]Dar T,Afzal MR,Yarlagadda B,et al.Mechanical function of the left atrium is improved with epicardial ligation of the left atrial appendage:Insights from the LAFIT-LARIAT registry.Heart Rhythm,2018,15(7):955-959.
• [8]Rodeheffer RJ,Naruse M,Atkinson JB,et al.Molecular forms of atrial natriuretic factor in normal and failing human myocardium.Circulation,1993,88(2):364-371.
• [9]Tabata T,Oki T,Yamada H,et al.Relationship between left atrial appendage function and plasma concentration of atrial natriuretic peptide.Eur J Echocardiogr,2000,1(2):130-137.
• [10]Takada T,Yasaka M,Nagatsuka K,et al.Blood flow in the left atrial appendage and embolic stroke in nonvalvular atrial fibrillation.Eur Neurol,2001,46(3):148-152.
• [11]Vigna C,Russo A,De Rito V,et al.Frequency of left atrial thrombi by transesophageal echocardiography in idiopathic and in ischemic dilated cardiomyopathy.Am J Cardiol,1992,70(18):1500-1501.
• [12]Frustaci A,Chimenti C,Bellocci F,et al.Histological substrate of atrial biopsies in patients with lone atrial fibrillation.Circulation,1997,96(4):1180-1184.
• [13]Manning WJ,Silverman DI,Keighley CS,et al.Transesophageal echocardiographically f acilitated early cardioversion f rom atrial f ibrillation using short-term anticoagulation:f inal results of a prospective 4.5-year study.J Am Coll Cardiol,1995,25(6):1354-1361.
• [14]Di Biase L,Santangeli P,Anselmino M,et al.Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation?Results from a multicenter study.J Am Coll Cardiol,2012,60(6):531-538.
• [15]Landmesser U,Holmes DR Jr.Left atrial appendage closure:a percutaneous transcatheter approach for stroke prevention in atrial fibrillation.Eur Heart J,2012,33(6):698-704.
• [16]Bayard YL,Omran H,Neuzil P,et al.PLAATO(percutaneous lef t atrial appendage transcatheter occlusion)for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients:results from the European PLAATO study.EuroIntervention,2010,6(2):220-226.
• [17]Boersma LV,Ince H,Kische S,et al.Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation:1-Year followup outcome data of the EWOLUTION trial.Heart Rhythm,2017,14(9):1302-1308.
• [18]Reddy VY,Holmes D,Doshi SK,et al.Safety of percutaneous left atrial appendage closure:results from the Watchman left atrial appendage system for embolic protection in patients with AF(PROTECT AF)clinical trial and the continued access registry.Circulation,2011,123(4):417-424.
• [19]Holmes DR Jr,Doshi SK,Kar S,et al.Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation:a patient-level Meta-analysis.J Am Coll Cardiol,2015,65(24):2614-2623.
• [20]Holmes DR Jr,Kar S,Price MJ,et al.Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy:the PREVAIL trial.J Am Coll Cardiol,2014,64(1):1-12.
• [21]Reddy VY,Doshi SK,Kar S,et al.5-Year Outcomes After Left Atrial Appendage Closure:From the PREVAIL and PROTECTAF Trials.J Ame Coll Cardiol,2017,70(24):2964-2975.
• [22]Bergmann MW,Ince H,Kische S,et al.Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy:results of the DAPT subgroup f rom the EWOLUTION all-comers study.EuroIntervention,2018,13(17):2003-2011.
• [23]Reddy VY,M?bius-Winkler S,Miller MA,et al.Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation:the ASAP study(ASA plavix feasibility study with watchman left atrial appendage closure technology).J Am Coll Cardiol,2013,61(25):2551-2556.
• [24]Landmesser U,Schmidt B,Nielsen-Kudsk JE,et al.Left atrial appendage occlusion with the AMPLATZER Amulet device:periprocedural and early clinical/echocardiographic data from a global prospective observational study.EuroIntervention,2017,13(7):867-876.
• [25]Huang H,Liu Y,Xu Y,et al.Percutaneous left atrial appendage closure with the lambre device for stroke prevention in atrial fibrillation:a prospective,multicenter clinical study.JACCCardiovasc Interv,2017,10(21):2188-2194.
• [26]Park JW,Sievert H,Kleinecke C,et al.Left atrial appendage occlusion with lambre in atrial fibrillation:Initial European experience.Int J Cardiol,2018,265:97-102.
• [27]Lakkireddy D,Turagam M,Afzal MR,et al.Left atrial appendage closure and systemic homeostasis:the LAA HOMEOSTASISstudy.J Am Coll Cardiol,2018,71(2):135-144.
• [28]Fauchier L,Cinaud A,Brigadeau F,et al.Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation.J Am Coll Cardiol,2018,71(14):1528-1536.
• [29]Urena M,Rodés-Cabau J,Freixa X,et al.Percutaneous lef t atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy.J Am Coll Cardiol,2013,62(2):96-102.
• [30]Dukkipati SR,Kar S,Holmes JD,et al.Device-related thrombus af ter lef t atrial appendage closure:incidence,predictors,and outcomes.Circulation,2018.[Epub ahead of print]
• [31]Reddy VY,Akehurst RL,Armstrong SO,et al.Time to costeff ectiveness f ollowing stroke reduction strategies in AF:warfarin versus NOACs versus LAA closure.J Am Coll Cardiol,2015,66(24):2728-2739.
• [32]Reddy VY,Akehurst RL,Armstrong SO,et al.Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.Europace,2016,18(7):979-986.
• [33]Casu G,Gulizia MM,Molon G,et al.ANMCO/AIAC/SICI-GISE/SIC/SICCH consensus document:percutaneous lef t atrial appendage occlusion in patients with nonvalvular atrial fibrillation:indications,patient selection,competences,organization,and operator training.G Ital Cardiol(Rome),2016,17(7-8):594-613.